Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by AngelMan92on Jul 03, 2020 12:10pm
116 Views
Post# 31220853

The Future of this Company

The Future of this Company

I was under the impression that this company was 100 million dollars in debt, when in reality that was just the amount of money grained from the outstanding shares sold by the company. 

 

With an actual debt of 2.6 million dollars US, this company has the potential of being so much more than I previously assessed. Why? Because without exception, Ive seen that when a company is shown to have no debt while operating at a profit, boom. The fact of the matter is that 2.6 million dollars can easily be thrown away by a single quarter's revenue of COVID testing, meaning they will be able to start operating at a profit and pay off the debt they aquired while creating Aristotle, well before the revolutionary product is set to release.

 

This is it bois, were gonna have a million dollar TFSA by year's end :D

Bullboard Posts